Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis

OBJECTIVE: The association between the use of renin–angiotensin–aldosterone (RAAS) inhibitors and the risk of mortality from COVID-19 is unclear. We aimed to estimate the association of RAAS inhibitors, including ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) with COVID-19 mortali...

Descripción completa

Detalles Bibliográficos
Autores principales: Ssentongo, Anna E, Ssentongo, Paddy, Heilbrunn, Emily S, Lekoubou, Alain, Du, Ping, Liao, Duanping, Oh, John S, Chinchilli, Vernon M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646321/
https://www.ncbi.nlm.nih.gov/pubmed/33154144
http://dx.doi.org/10.1136/openhrt-2020-001353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646321/
https://www.ncbi.nlm.nih.gov/pubmed/33154144
http://dx.doi.org/10.1136/openhrt-2020-001353

Ejemplares similares